Free Trial
NASDAQ:ENVB

Enveric Biosciences (ENVB) Stock Price, News & Analysis

Enveric Biosciences logo
$1.46 -0.06 (-3.96%)
As of 03:56 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Enveric Biosciences Stock (NASDAQ:ENVB)

Advanced

Key Stats

Today's Range
$1.45
▼
$1.54
50-Day Range
$1.37
▼
$1.62
52-Week Range
$1.17
▼
$13.25
Volume
31,355 shs
Average Volume
1.24 million shs
Market Capitalization
$6.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Enveric Biosciences is a biotechnology company developing small-molecule treatments for mental health conditions. Its research focuses on neuroplastogens—compounds designed to promote changes in neural connections—with potential applications in disorders such as depression and anxiety.

The company uses its Psybrary platform, a library of compounds inspired by psychedelic molecules, to identify and develop therapeutic candidates. Its programs are in development, and the company’s work is focused on research rather than marketed medicines.

Enveric expanded into psychedelic-inspired drug discovery through its 2021 acquisition of MagicMed Industries. It is headquartered in Naples, Florida.

AI Generated. May Contain Errors.

Enveric Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
27th Percentile Overall Score

ENVB MarketRank™: 
1.3480911983 of 5 stars

Enveric Biosciences scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Enveric Biosciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Enveric Biosciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Enveric Biosciences' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Enveric Biosciences is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Enveric Biosciences is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Enveric Biosciences has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.45% of the float of Enveric Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Enveric Biosciences has a short interest ratio ("days to cover") of 0.56, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Enveric Biosciences has recently decreased by 49.31%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Enveric Biosciences does not currently pay a dividend.

  • Dividend Growth

    Enveric Biosciences does not have a long track record of dividend growth.

  • News Sentiment

    Enveric Biosciences has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Enveric Biosciences this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for ENVB on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Enveric Biosciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Enveric Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    2.41% of the stock of Enveric Biosciences is held by insiders.

  • Percentage Held by Institutions

    13.82% of the stock of Enveric Biosciences is held by institutions.

  • Read more about Enveric Biosciences' insider trading history.
Receive ENVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enveric Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ENVB Stock News Headlines

Buy Stocks… A Crash is Coming
Think stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges investors not to sell before hearing his 2027 prediction. He warns that by November 30th, Congress is set to make a move he believes will trigger a historic buying panic. Economists call the phenomenon a crack-up boom. Rickards is known for correctly predicting the biggest market shocks of the last 20 years.tc pixel
Enveric Biosciences Inc ENVB
See More Headlines

ENVB Stock Analysis - Frequently Asked Questions

Enveric Biosciences' stock was trading at $3.63 on January 1st, 2026. Since then, ENVB stock has decreased by 59.9% and is now trading at $1.4550.

Enveric Biosciences, Inc. (NASDAQ:ENVB) issued its quarterly earnings results on Friday, November, 13th. The company reported ($0.57) EPS for the quarter.

Enveric Biosciences shares reverse split on the morning of Wednesday, January 29th 2025.The 1-15 reverse split was announced on Tuesday, January 21st 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 28th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Top institutional investors of Enveric Biosciences include StoneX Group Inc. (0.63%).
View institutional ownership trends
.

Shares of ENVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enveric Biosciences investors own include Palantir Technologies (PLTR), MARA (MARA), NVIDIA (NVDA), Tonix Pharmaceuticals (TNXP), Tesla (TSLA), AMC Entertainment (AMC) and IonQ (IONQ).

Company Calendar

Last Earnings
11/13/2026
Today
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ENVB
CIK
890821
Employees
6
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($12.65)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.77 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-162.87%
Return on Assets
-144.23%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.21
Quick Ratio
10.21

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.00 per share
Price / Book
0.21

Miscellaneous

Outstanding Shares
4,476,000
Free Float
4,368,000
Market Cap
$6.58 million
Optionable
Not Optionable
Beta
1.23
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (NASDAQ:ENVB) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners